M
Martin Gutierrez
Researcher at Hackensack University Medical Center
Publications - 236
Citations - 10574
Martin Gutierrez is an academic researcher from Hackensack University Medical Center. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 40, co-authored 187 publications receiving 8966 citations. Previous affiliations of Martin Gutierrez include National Institutes of Health & Rutgers University.
Papers
More filters
Journal ArticleDOI
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell,Alexander M. Lesokhin,Alexander M. Lesokhin,Ivan Borrello,Ahmad Halwani,Emma C. Scott,Martin Gutierrez,Stephen J. Schuster,Michael Millenson,Deepika Cattry,Gordon J. Freeman,Scott J. Rodig,Bjoern Chapuy,Azra H. Ligon,Lili Zhu,Joseph F. Grosso,Su Y oung Kim,John M. Timmerman,Margaret A. Shipp,Philippe Armand +19 more
TL;DR: Nivolumab had substantial therapeutic activity and an acceptable safety profile in patients with previously heavily treated relapsed or refractory Hodgkin's lymphoma.
Journal ArticleDOI
Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase ib study
Alexander M. Lesokhin,Alexander M. Lesokhin,Stephen M. Ansell,Philippe Armand,Emma C. Scott,Ahmad Halwani,Martin Gutierrez,Michael Millenson,Adam D. Cohen,Stephen J. Schuster,Daniel Lebovic,Madhav V. Dhodapkar,David Avigan,Bjoern Chapuy,Azra H. Ligon,Gordon J. Freeman,Scott J. Rodig,Deepika Cattry,Lili Zhu,Joseph F. Grosso,M. Brigid Bradley Garelik,Margaret A. Shipp,Ivan Borrello,John M. Timmerman +23 more
TL;DR: Nivolumab was well tolerated and exhibited antitumor activity in extensively pretreated patients with relapsed or refractory B- and T-cell lymphomas and PD-L1/PD-L2 locus integrity and protein expression.
Journal ArticleDOI
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.
Neal Ready,Matthew D. Hellmann,Mark M. Awad,Gregory A. Otterson,Martin Gutierrez,Justin F. Gainor,Hossein Borghaei,Jacques Jolivet,Leora Horn,Mihaela Mates,Julie R. Brahmer,Ian Rabinowitz,Pavan S. Reddy,Jason Chesney,James Michael Orcutt,David R. Spigel,Martin Reck,Kenneth J. O'Byrne,Luis Paz-Ares,Wenhua Hu,Kim E. Zerba,Xuemei Li,Brian Lestini,William J. Geese,Joseph D. Szustakowski,George Green,Han Chang,Suresh S. Ramalingam +27 more
TL;DR: TMB of 10 or more mut/Mb was associated with improved response and prolonged progression-free survival in both tumor PD-L1 expression 1% or greater and less than 1% subgroups and was thus identified as a potentially relevant cutoff in the assessment of TMB as a biomarker for first-line nivolumab plus ipilimumab.
Journal ArticleDOI
Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology
Richard F. Little,Stefania Pittaluga,Nicole Grant,Seth M. Steinberg,Mark F. Kavlick,Hiroaki Mitsuya,Genoveffa Franchini,Martin Gutierrez,Mark Raffeld,Elaine S. Jaffe,Gene M. Shearer,Robert Yarchoan,Wyndham H. Wilson +12 more
TL;DR: The results suggest that the improved immune function associated with highly active antiretroviral therapy (HAART) may have led to a shift in pathogenesis away from lymphomas of post-germinal center origin, which have a poor prognosis.
Journal ArticleDOI
Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies
Shivaani Kummar,Robert J. Kinders,Martin Gutierrez,Larry Rubinstein,Ralph E. Parchment,Lawrence R. Phillips,Jiuping Ji,Anne Monks,Jennifer A. Low,Alice P. Chen,Anthony J. Murgo,Jerry M. Collins,Seth M. Steinberg,Helen Eliopoulos,Vincent L. Giranda,Gary B. Gordon,Lee J. Helman,Robert H. Wiltrout,Joseph E. Tomaszewski,James H. Doroshow +19 more
TL;DR: The rapid conclusion of this trial demonstrates the feasibility of conducting proof-of-principle phase 0 trials as part of an alternative paradigm for early drug development in oncology.